SIRPA and neoplasm: Concurrently, the anti-CD47 antibody competitively binds CD47 on the tumor cell membrane, disrupting the CD47–SIRPα axis and lifting the “don’t eat me” signal, thereby enabling macrophage-mediated phagocytosis of the tumor cells.